Thus, it was observed that 8% of “pan-negative” melanomas display non-V600 exon 15 BRAF mutations [55]; 4–8% contain activating BRAF fusions, both of which are sensitive to MEK inhibition [56]. This evidence concerns the gene MAP2K7 and melanoma.